Kura Oncology Croissance future

Future contrôle des critères 2/6

Kura Oncology devrait augmenter ses bénéfices et son chiffre d'affaires de 26.5% et de 65.6% par an respectivement. Le BPA devrait croître de de 29.8% par an. Le rendement des capitaux propres devrait être -59.9% dans 3 ans.

Informations clés

26.5%

Taux de croissance des bénéfices

29.8%

Taux de croissance du BPA

Biotechs croissance des bénéfices	27.3%
Taux de croissance des recettes	65.6%
Rendement futur des capitaux propres	-59.9%
Couverture par les analystes	Good
Dernière mise à jour	24 Oct 2024

Mises à jour récentes de la croissance future

Recent updates

Kura Oncology, Inc.'s (NASDAQ:KURA) Intrinsic Value Is Potentially 72% Above Its Share Price

Jan 25

Is Kura Oncology (NASDAQ:KURA) A Risky Investment?

Aug 14

Is Kura Oncology (NASDAQ:KURA) Using Debt Sensibly?

Apr 04

Is There An Opportunity With Kura Oncology, Inc.'s (NASDAQ:KURA) 44% Undervaluation?

Jan 31

Kura Oncology (NASDAQ:KURA) Is In A Good Position To Deliver On Growth Plans

Oct 10

Kura Oncology stock rises 7% as Cantor Fitzgerald begins coverage with Overweight rating

Jul 13

We Think Kura Oncology (NASDAQ:KURA) Can Afford To Drive Business Growth

Jun 26

We're Not Very Worried About Kura Oncology's (NASDAQ:KURA) Cash Burn Rate

Nov 23

We're Not Very Worried About Kura Oncology's (NASDAQ:KURA) Cash Burn Rate

Aug 09

Kura Oncology Investor Presentation - Slideshow

May 08

What Kind Of Shareholders Hold The Majority In Kura Oncology, Inc.'s (NASDAQ:KURA) Shares?

Dec 14

Kura Oncology: Advanced Precision Medicine Opportunity Excites, But Not Without Risks

Dec 10

Kura Oncology (KURA) Presents At ASH Virtual Investor Event

Dec 08

Kura Oncology Jumps 16% After Announcing First In-Human Data for AML Candidate

Dec 07

Kura Oncology (KURA) Presents At Stifel Healthcare Conference - Slideshow

Nov 17

Prévisions de croissance des bénéfices et des revenus

NasdaqGS:KURA - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	99	-206	-189	-201	12
12/31/2025	9	-239	-197	-203	14
12/31/2024	N/A	-212	-168	-185	13
6/30/2024	N/A	-182	-155	-155	N/A
3/31/2024	N/A	-168	-138	-138	N/A
12/31/2023	N/A	-153	-125	-125	N/A
9/30/2023	N/A	-143	-117	-117	N/A
6/30/2023	N/A	-140	-110	-109	N/A
3/31/2023	N/A	-137	-114	-114	N/A
12/31/2022	N/A	-136	-111	-110	N/A
9/30/2022	N/A	-135	-108	-107	N/A
6/30/2022	N/A	-133	-112	-110	N/A
3/31/2022	N/A	-132	-109	-108	N/A
12/31/2021	N/A	-130	-106	-105	N/A
9/30/2021	N/A	-124	-101	-99	N/A
6/30/2021	N/A	-114	-93	-92	N/A
3/31/2021	N/A	-101	-80	-79	N/A
12/31/2020	N/A	-90	-72	-70	N/A
9/30/2020	N/A	-81	-67	-65	N/A
6/30/2020	N/A	-74	-62	-61	N/A
3/31/2020	N/A	-68	-61	-60	N/A
12/31/2019	N/A	-63	-55	-55	N/A
9/30/2019	N/A	-61	-51	-51	N/A
6/30/2019	N/A	-60	-52	-52	N/A
3/31/2019	N/A	-60	-50	-50	N/A
12/31/2018	N/A	-60	-49	-49	N/A
9/30/2018	N/A	-55	-46	-46	N/A
6/30/2018	N/A	-49	-39	-39	N/A
3/31/2018	N/A	-43	N/A	-33	N/A
12/31/2017	N/A	-35	N/A	-28	N/A
9/30/2017	N/A	-32	N/A	-28	N/A
6/30/2017	N/A	-30	N/A	-27	N/A
3/31/2017	N/A	-28	N/A	-27	N/A
12/31/2016	N/A	-28	N/A	-25	N/A
9/30/2016	N/A	-27	N/A	-24	N/A
6/30/2016	N/A	-26	N/A	-23	N/A
3/31/2016	N/A	-25	N/A	-21	N/A
12/31/2015	N/A	-23	N/A	-18	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: KURA devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: KURA devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: KURA devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de KURA ( 65.6% par an) devrait croître plus rapidement que le marché US ( 8.8% par an).

Croissance élevée des revenus: Le chiffre d'affaires de KURA ( 65.6% par an) devrait croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: KURA devrait être non rentable dans 3 ans.

Kura Oncology Croissance future

Future contrôle des critères 2/6

Informations clés

Mises à jour récentes de la croissance future

Price target decreased by 10% to US$28.46

Price target decreased to US$32.67

Price target decreased to US$38.43

Price target decreased to US$41.63

Recent updates

Kura Oncology (NASDAQ:KURA) Has Debt But No Earnings; Should You Worry?

Kura Oncology, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Kura Oncology, Inc. Appoints Michael Vasconcelles to Its Board of Directors

Kura Oncology: The Long Holding Pattern Is Risky

Kura Oncology Announces Fda Clearance of Ind Application for Menin Inhibitor Ziftomenib in Advanced Gastrointestinal Stromal Tumors (Gist)

Kura Oncology, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Estimating The Fair Value Of Kura Oncology, Inc. (NASDAQ:KURA)

Now 20% undervalued after recent price drop

Kura Oncology, Inc.(NasdaqGS:KURA) dropped from Russell 2500 Value Index

Insufficient new directors

Kura Oncology, Inc. Completes Enrollment of 85 Patients in the Phase 2 Portion of KOMET-001

Now 21% overvalued after recent price rise

Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML

Is Kura Oncology (NASDAQ:KURA) Using Debt Sensibly?

Kura Oncology: Balancing Act Of Promise And Pragmatism

Kura Oncology, Inc. to Report Q1, 2024 Results on May 02, 2024

Kura Oncology, Inc. Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML

Kura Oncology, Inc., Annual General Meeting, Jun 05, 2024

Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma

Kura Oncology, Inc. Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia

Kura Oncology, Inc. to Report Fiscal Year 2023 Results on Feb 27, 2024

Kura Oncology: Ziftomenib's Path To AML Market Widens

Kura Oncology, Inc. Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia

Chairman notifies of intention to sell stock

Kura Oncology, Inc.'s (NASDAQ:KURA) Intrinsic Value Is Potentially 72% Above Its Share Price

New minor risk - Share price stability

Kura Oncology, Inc. announced that it expects to receive $150 million in funding from EcoR1 Capital, LLC

Price target decreased by 10% to US$28.46

Kura Oncology, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Kura Oncology, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Kura Oncology, Inc. Announces First Patient Dosed in Fit-001 Trial of Next-Generation Farnesyl Transferase Inhibitor KO-2806

Kura Oncology Reports Preclinical Data Showing Ability of KO-2806 to Enhance Antitumor Activity of KRASG12C Inhibitors in Non-Small Cell Lung Cancer

Kura Oncology Appoints Brian Powl as Chief Commercial Officer

Is Kura Oncology (NASDAQ:KURA) A Risky Investment?

Kura Oncology, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Kura Oncology, Inc. has completed a Follow-on Equity Offering in the amount of $99.999707 million.

Kura Oncology, Inc. Presents Late-Breaking Clinical Data for Menin Inhibitor Ziftomenib At 2023 European Hematology Association Congress

Kura Oncology, Inc. to Report Q1, 2023 Results on May 10, 2023

Is Kura Oncology (NASDAQ:KURA) Using Debt Sensibly?

Kura Oncology, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Kura Oncology, Inc. Announces First Patients Dosed in Phase 2 Registration-Directed Trial of Ziftomenib in NPM1-Mutant Acute Myeloid Leukemia

Chief Medical Officer recently sold US$61k worth of stock

Is There An Opportunity With Kura Oncology, Inc.'s (NASDAQ:KURA) 44% Undervaluation?

Kura Oncology Announces FDA Clearance of IND Application for KO-2806, A Next-Generation Farnesyl Transferase Inhibitor

Kura Oncology Presents Updated Clinical Data from KOMET-001 Trial of Menin Inhibitor Ziftomenib

Kura Oncology, Inc. announced that it expects to receive $150.000003 million in funding from Bristol-Myers Squibb Company,

Kura Oncology, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Kura Oncology, Inc. Reports Preliminary Proof of Mechanism in Phase 1/2 Clinical Trial of Tipifarnib Plus Alpelisib in Head and Neck Squamous Cell Carcinoma

Kura Oncology (NASDAQ:KURA) Is In A Good Position To Deliver On Growth Plans

Price target decreased to US$32.67

Kura Oncology, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Kura Oncology stock rises 7% as Cantor Fitzgerald begins coverage with Overweight rating

We Think Kura Oncology (NASDAQ:KURA) Can Afford To Drive Business Growth

Kura Oncology, Inc. Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Emergence of Resistance to Osimertinib in Non-Small Cell Lung Cancer

Kura Oncology, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Kura Oncology, Inc. Announces Executive Changes

Kura Oncology, Inc. Announces Executive Changes

Kura Oncology, Inc. Receives FDA Authorization to Proceed with Phase 1b Study of KO-539 in Acute Myeloid Leukemia

Kura Oncology, Inc. Doses First Patient in Phase 1/2 Clinical Trial of Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma

Kura Oncology, Inc. Reports Final Results from Phase 2 Study of Tipifarnib in T-Cell Lymphoma

Kura Oncology Provides Update on Phase 1b Study of KO-539 in Acute Myeloid Leukemia

Price target decreased to US$38.43

We're Not Very Worried About Kura Oncology's (NASDAQ:KURA) Cash Burn Rate

Insider notifies of intention to sell stock

We're Not Very Worried About Kura Oncology's (NASDAQ:KURA) Cash Burn Rate

Independent Director Robert Hoffman has left the company

Kura Oncology, Inc.(NasdaqGS:KURA) dropped from Russell 3000E Index

Kura Oncology Doses First Patient in Phase 1b Expansion Cohorts with Menin Inhibitor KO-539

Kura Oncology Investor Presentation - Slideshow

Price target decreased to US$41.63

Chief Operating Officer exercised options and sold US$63k worth of stock